The Biopharmaceutical Development Program (BDP) at Frederick National Laboratory is engineering cells into cancer-killers that are being used to treat children and young adults participating in early-phase pediatric cancer trials.
The treatment is called chimeric antigen receptor (CAR) T cell therapy. CAR T cells are a type of white blood cell…